HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of central precocious puberty.

AbstractPURPOSE OF REVIEW:
In consideration of the large number of the rapid advances in this area, it seems appropriate to highlight some of the recent studies that address factors involved in the decision to treat a child with central precocious puberty, and two recent advances in drug therapy.
RECENT FINDINGS:
There are still many areas of uncertainty regarding treatment of central precocious puberty, including the hormonal test results that support the diagnosis, the best way to predict adult height, and the effect of the age of the child on the amount of height gained during treatment (adult height minus predicted height). Many studies show that children with onset of symptoms before age 6 benefit the most, but a recent study showed no difference in height benefit between girls initially seen at at least 7 or more than 7 years. Two reports indicate that greater delay from the onset of puberty to the start of therapy with gonadotropin-releasing hormone analogue has a negative effect on adult height. Although there has been considerable experience with monthly injections of gonadotropin-releasing hormone analogues to suppress pubertal development, recent studies show that a slower released formulation given every 3 months is also effective in the majority of patients. The newest form of therapy involves a subcutaneous implant of the gonadotropin-releasing hormone analogue histrelin, which gives excellent gonadotropin suppression for 12 months.
SUMMARY:
Treatment of central precocious puberty continues to be a very active area of clinical investigation, but there are still unresolved questions that future studies will need to address.
AuthorsPaul B Kaplowitz
JournalCurrent opinion in endocrinology, diabetes, and obesity (Curr Opin Endocrinol Diabetes Obes) Vol. 16 Issue 1 Pg. 31-6 (Feb 2009) ISSN: 1752-2978 [Electronic] England
PMID19104235 (Publication Type: Journal Article, Review)
Chemical References
  • Luteolytic Agents
  • Triptorelin Pamoate
  • Luteinizing Hormone
Topics
  • Adult
  • Body Height
  • Breast (growth & development)
  • Child
  • Female
  • Humans
  • Luteinizing Hormone (blood)
  • Luteolytic Agents (therapeutic use)
  • Male
  • Puberty, Precocious (diagnosis, drug therapy, etiology)
  • Sex Characteristics
  • Triptorelin Pamoate (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: